A representative metaphase from patient 2 hybridized with the LSI IGH/CCND1 dual-color probe. The CCND1 signals on the two normal chromosomes 11 are shown in red. The IGH signal on the normal chromosome 14 is shown in green (pink arrow) and the split IGH signal is present on the derived chromosomes 8 (5′ IGH) (white arrow) and 14 (3′ IGH) (yellow arrow).
Figure 1
A representative metaphase from patient 2 hybridized with the LSI IGH/CCND1 dual-color probe. The CCND1 signals on the two normal chromosomes 11 are shown in red. The IGH signal on the normal chromosome 14 is shown in green (pink arrow) and the split IGH signal is present on the derived chromosomes 8 (5′ IGH) (white arrow) and 14 (3′ IGH) (yellow arrow).
Use of serum-free media to minimize apoptosis of chronic lymphocytic leukemia cells during in vitro culture

TO THE EDITOR
Chronic lymphocytic leukemia (B-CLL) is a hematologic malignancy that afflicts middle-aged and elderly individuals and is characterized by the accumulation of long-lived non-dividing CD5 + B cells in G 0 of the cell cycle. 1 Although B-CLL cells are long-lived in vivo, they undergo rapid and spontaneous apoptosis when cultured in vitro. 2 B-CLL cells express the anti-apoptotic protein bcl-2, which may promote their viability and resistance to apoptosis in vivo. 3 Bcl-2 levels decrease during in vitro culture of B-CLL cells and bcl-2 levels are inversely correlated with the susceptibility of cultured B-CLL cells to undergo spontaneous apoptosis. 4 The spontaneous apoptosis of B-CLL cells during in vitro culture provides both a challenge and opportunity to understand B-CLL cell biology. Understanding the factors that maintain B-CLL cell viability in vitro may identify factors necessary for B-CLL cell viability in vivo. Studies performed by Rosen and coworkers 5 indicated increased viability of B-CLL cells during in vitro culture in Iscove's modification of Dulbecco's medium supplemented with bovine serum albumin, transferrin and 2-mercaptoethanol. This same group has also recently shown that the addition of thioredoxin to B-CLL culture media containing RPMI and 10% FBS improved B-CLL viability during in vitro culture. 6 Unfortunately, the expense and lability of thioredoxin precludes its routine use in B-CLL culture media. We therefore tested the ability of several different media preparations to maintain B-CLL cell viability and bcl-2 levels during in vitro culture.
Patients with CD5 + B-CLL were recruited from clinics at Duke University and Durham VA Medical Centers. B-CLL cells were isolated from patients with peripheral blood white counts greater than 20 000/l and who had not received B-CLL therapy in the last month. Informed consent was obtained as part of a protocol approved by the Duke University and Durham VA Institutional Review Boards. PBMC were isolated from B-CLL patient peripheral blood samples using Ficoll-Hypaque density gradients. B-CLL cells were purified by depletion of T cells and macrophages using magnetic beads coupled with anti-CD2 and anti-CD14 antibodies, respectively, according to the manufacturer's instructions (Dynal, Lake Success, NY, USA). The purity of these T cell-and macrophage-depleted B-CLL preparations (n = 25 B-CLL preparations from 19 patients) was determined by flow cytometry and on average (±s.e.m.) were 95% ± 0.9% CD5 + /CD19 + , 1.1% ± 0.3% CD5 supplements were all from GibcoBRL (Grand Island, NY, USA) unless otherwise indicated and included Hybridoma SFM with insulin, transferrin and L-glutamine (catalog 12045-076), AIM-V with human serum albumin, L-glutamine, streptomycin sulfate and gentamicin sulfate (catalog 12055-091), RPMI 1640 with L-glutamine (RPMI) (catalog 11875-093) and Iscove's modified Dulbecco's medium with L-glutamine and HEPES (Iscove's media) (catalog 12440-093). Media were also supplemented with heat-inactivated (56°C for 30 min) fetal bovine serum (FBS) (Sigma, St Louis, MO, USA), bovine serum albumin (BSA) (catalog 15260-037), 2-mercaptoetanol (2-ME) (catalog 21985-023) and/or insulin-transferrin-selenium (ITS) (stock solution = 10 mg/ml insulin, 5.5 mg/l transferrin, 6.7 g/l sodium selenite, 110 mg/l sodium pyruvate and 2 mg/l ethanolamine) (catalog 71200-042).
We cultured B-CLL cells in Hybridoma SFM, AIM-V, RPMI with 10% FBS, Iscove's media and Iscove's media with 0.04% BSA, 1% ITS and 55 M 2-ME (Rosen et al 5 ) for 1 to 14 days and determined the viability of cultured B-CLL cells from seven B-CLL samples from seven different B-CLL patients using a flow cytometry-based propidium iodide exclusion assay. We found that culture in Hybridoma SFM or AIM V maintained B-CLL cell viability (110% ± 7.6% and 110% ± 8.2% viability relative to the day of culture, respectively, n = 7) following 3 days of culture. B-CLL cells cultured in Hybridoma SFM were significantly more viable than B-CLL cells cultured in RPMI with FBS (P = 0.0277) for 3 days (Figure 1a) . Furthermore, following 7 days of culture, there was a significant reduction in B-CLL cell viability as compared to day 0 during in vitro culture in RPMI with FBS (P = 0.0277), Iscove's media (P = 0.0280) and Iscove's media with 0.04% BSA, 1% ITS and 55 M 2-ME (P = 0.0464), but not in Hybridoma SFM and AIM V (n = 6 or 7). To confirm the ability of Hybridoma SFM to maintain B-CLL cell viability during in vitro culture, we tested the viability of an additional 17 B-CLL cell samples from 14 different B-CLL patients in Hybridoma SFM; we found that B-CLL cell viability was 110% ± 6.9% following 3 days of in vitro culture in Hybridoma SFM (Figure 1b) . The average percentage of dead cells ((propidium iodide positive events/the number of cells plated) × 100) in B-CLL cells cultured in Hybridoma SFM was 9.7% (s.e.m. = 4.0%, median = 4.3%, range 1.9% to 98.4%). 22/24 of these samples had 10.3% or less dead cells. This indicates that the excellent viability of B-CLL cells cultured in Hybridoma SFM for 3 days was related to the absence of B-CLL cell apoptosis and not due primarily to apoptosis of some and proliferation of other B-CLL cells in individual patient samples.
We also determined whether the viability of B-CLL cells cultured in vitro correlated with B-CLL cell bcl-2 levels (Figure 2 ). There was a significant correlation (corr. coef. = 0.59, P = 0.0064) between B-CLL cell viability and bcl-2 levels following culture in Hybridoma SFM, AIM-V, RPMI with 10% FBS, Iscove's media and Iscove's media with 0.04% BSA, 1% ITS and 55 M 2-ME for 1, 3, 7 and 14 days (Figure 2) . The correlation between B-CLL viability and bcl-2 levels was increased when samples from only days 1, 3 and 7 were analyzed (corr. coef. = 0.90, P Ͻ 0.0001).
The factors that promote B-CLL cell survival during in vitro culture in Hybridoma SFM and AIM V are not known. Gibco/BRL has not released the contents of both products. Both products contain minimal amounts of protein. Insulin and transferrin are the only proteins in Hybridoma SFM. AIM V contains insulin and transferrin, and human serum albumin at a concentration of 0.2 g/dl. Because ITS and human serum albumin diminished the viability of B-CLL cells cultured in Hybridoma SFM and did not improve the viability of B-CLL cells cultured in RPMI or Iscove's media (data not shown), it seems likely that other non-protein factors in Hybridoma SFM and AIM V may promote B-CLL viability during in vitro culture.
Several protein factors have been shown to maintain B-CLL cell viability during in vitro culture. Of likely importance in vivo, cytokines, such as IL-4, prevent B-CLL cell apoptosis during in vitro culture. 7 The IL-4-mediated mechanisms that permit B-CLL cell survival
Figure 2
Correlation of B-CLL cell viability and bcl-2 levels during in vitro culture in different media. B-CLL cells were isolated, purified and cultured in either Hybridoma SFM, AIM-V, RPMI with 10% FBS, Iscove's media and Iscove's media with 0.04% BSA, 1% ITS and 55 M 2-ME for 1 to 14 days as described in Figure 1 (n = 5). Following culture, B-CLL cells were harvested and relative viability was determined with the flow-cytometry based propidium-iodide exclusion assay as described in Figure 1 . Bcl-2 levels were determined as previously described. 6 Briefly, 2. during in vitro culture are not completely understood; IL-4 has been shown to increase B-CLL cell bcl-2 levels. 7 Two other factors of likely importance in vivo, IL-2 and thioredoxin not only promote B-CLL survival during in vitro culture, but also permit B-CLL cell growth and infection with Epstein-Barr virus. 6, 8 Thioredoxin maintains B-CLL cell bcl-2 levels during in vitro culture and induces B-CLL cell TNF␣ secretion. 6 The addition of 2-ME to lymphocyte cultures may mimic some of the effects of thioredoxin. 8 However, neither Hybridoma SFM nor AIM V contain 2-ME. A non-protein molecule that mimics the effects of thioredoxin may be a possible factor that promotes B-CLL cell viability in Hybridoma SFM and AIM V. For this reason, we tested the effect Leukemia of adding reduced L-glutathione, L-cysteine and L-cystine to RPMI and the effect of removing these agents from Hybridoma SFM and did not observe a difference in the viability of cultured B-CLL cells (data not shown). Therefore, the identity of the factors in Hybridoma SFM and AIM V that promote the viability of B-CLL cells in vitro remain unknown.
In summary, we have described a practical, inexpensive method to maintain B-CLL cell viability during in vitro culture in the serum-free media Hybridoma SFM and AIM V; this is likely to improve studies of B-CLL cell metabolism and in vitro drug cytotoxicity. An analysis of serum and media components that regulate B-CLL viability may yield insights into B-CLL cell growth in vivo and strategies for therapeutically limiting B-CLL cell expansion in patients. 
